42 results about "Intestinal fluid" patented technology

The invention belongs to the technical field of preparation of probiotics, and provides a bacterial strain with anti-allergic and immunity-improving effects and application of the bacterial strain. According to the method, a three-layer physical self-assembly structure is adopted, and polysaccharide-polyphenol layer-by-layer self-assembly coating treatment, lipid insertion layer treatment and calcium ion crosslinking protection coating treatment are sequentially carried out. And mannan oligosaccharide MOS and / or galactooligosaccharide GOS are / is mixed in the chitosan layer in a ratio of 0.05-0.15% w / v, and the surface sugar ligand density reaches 4-8 [mu] g per 10 CFU. The coating is constructed under the condition that the pH value is 5.4-5.8; the thickness of the lipid layer is 20-80 nm when the pH value is 5.6-6.2; the cross-linked layer is treated at the pH of 6.0-6.5, so that the gastric acid environment is stable for 2 hours, and the gastric acid is controllably released in intestinal juice for 2-4 hours. The prepared strain has the total thickness of 220-900 nm, the outermost layer coverage rate is larger than or equal to 85%, the gastric juice survival rate is remarkably improved, the strain can be prepared into an oral preparation to be used for preventing and relieving allergic diseases, the viable count of each dose is 1 * 10 <-1 > * 10 <-1 > CFU, and the process is mild and suitable for industrial production.

This application relates to the field of functional composition technology, and in particular to a GABA-vitamin D neuroprotective composition and its preparation method, comprising medium-chain triglycerides, modified phospholipids, and a GABA-vitamin D blend. This application utilizes the low interfacial tension and strong amphiphilic compatibility of medium-chain triglycerides and modified phospholipids, enabling them to be miscible with the blend, thus improving the characteristics of GABA and vitamin D being easily degraded and oxidatively inactivated under complex physiological environments, and solving the problems of poor stability and asynchronous absorption. In the preparation method, the preferred component mass ratio is (0.6–1.5):1:(1–1.6), and mixing is carried out at 50–80°C for 10–60 min. The resulting system features high encapsulation efficiency, uniform particle size distribution, and high bioavailability. After treatment in simulated gastric fluid (pH 1.2) for 2 hours, the average GABA retention rate is ≥88% (optimal up to 94.3%), and the average vitamin D retention rate is ≥94% (optimal up to 96.8%). After treatment in simulated intestinal fluid (pH 6.8) for 4 hours, the simultaneous release rate of GABA and vitamin D is ≥90%, achieving precise intestinal delivery and making it suitable for industrial production.

The invention discloses a composite particle with a prebiotic function and colon-targeted co-delivery performance as well as a preparation method and application thereof, and belongs to the technical field of functional foods and intestinal micro-ecological regulators. According to the composite particle, the curcumin and the resveratrol are encapsulated by the peanut protein isolate to form a nano core, the outer layer of the nano core is a composite shell layer composed of the carboxymethyl konjac glucomannan and the prebiotics, a stable core-shell structure is formed, and the composite particle is small in particle size, good in dispersity and stability and good in stability. The stability of a protein-based delivery system in a gastrointestinal tract environment can be obviously improved; the release rate of the composite particles in simulated gastric juice and intestinal juice is low, and the composite particles can be specifically degraded and release active ingredients in simulated colon fluid containing beta-mannase, so that colon-targeted co-delivery can be realized. The composite particle disclosed by the invention is simple in preparation process and stable in function, can be applied to the fields of functional foods, health foods, formula foods for special medical purposes and the like, realizes dual purposes of active component delivery and intestinal microenvironment regulation, and has a wide application prospect.

This invention discloses a strain of Bifidobacterium animalis subspecies TRT-2A with allergy-relieving effects and its extracellular vesicle applications. The strain TRT-2A is deposited at the China Center for Type Culture Collection (CCTCC) on November 21, 2025, with accession number CCTCC NO:M 20252645. This strain is highly acid-resistant and exhibits good tolerance to artificial gastric and intestinal fluids. It effectively inhibits bacteria, particularly Streptococcus pyogenes, Streptococcus agalactiae, and / or Escherichia coli. Experimental results show that this strain can alleviate hormone-dependent dermatitis and effectively improve dermatitis symptoms such as erythema and desquamation. Furthermore, extracellular vesicles prepared using TRT-2A can effectively improve skin elasticity and reduce wrinkles. Therefore, the Bifidobacterium animalis subspecies TRT-2A of this invention has multiple functions and is worthy of further promotion and application.

The invention belongs to the technical field of biological medicines, and particularly relates to a multifunctional peptide and application thereof in anti-inflammatory, antibacterial, mucous membrane repair and intestinal secretion promotion. Specifically, the invention designs a polypeptide and an analogue which have guanylate cyclase C receptor (GUCY2C) agonist activity and anti-inflammatory, antibacterial and mucous membrane repair functions at the same time. The polypeptide can be combined with GUCY2C, stimulate generation of cyclic guanosine monophosphate (cGMP) in cells, promote intestinal fluid secretion, inhibit release of proinflammatory factors, relieve inflammatory response, promote repair of intestinal injury mucosa, inhibit growth of opportunistic pathogenic bacteria and accelerate intestinal homeostasis recovery after intestinal preparation. The composition can effectively promote intestinal tract cleaning, does not cause intestinal inflammation and mucosal lesion, has no hemolytic toxicity and cytotoxicity, is high in safety, and has a good clinical application prospect.

The invention relates to a colon-targeted micro-ecological regulation composition. The colon-targeted micro-ecological regulation composition is prepared by compounding the following functional components in percentage by weight: 5-95% of a component A, 1-15% of a component B and 4-94% of a component C, the component A is resistant starch, the polymerization degree DP is greater than or equal to 15, and the crystallinity is greater than or equal to 35%; the component B is probiotics and is embedded through a complex coacervation method or an extrusion-gel method, the embedding rate is larger than or equal to 75%, and the particle size is 200-800 microns; the survival rate is greater than or equal to 60% after treatment in simulated gastric juice for 2 hours, and the survival rate is greater than or equal to 50% after treatment in simulated intestinal juice for 4 hours; the component C comprises functional nutritional auxiliary materials, the functional nutritional auxiliary materials comprise prebiotics and a medicinal and edible composition, and the prebiotics comprise rapid fermentation type prebiotics, medium-speed fermentation type prebiotics, slow fermentation type prebiotics and a non-fermentation type water-holding expansion component. By constructing a carbon source slow release-flora orientation-metabolism regulation ternary interaction collaborative network, accurate regulation and multi-target metabolism intervention of the whole digestive tract are realized.

This invention discloses a strain of *Bacillus parabrachium* ABX1 and its applications, belonging to the field of beneficial microbial technology. The *Bacillus parabrachium* ABX1 provided by this invention is a Gram-positive bacterium isolated from the intestinal fluid of *Bombyx mori*. On CMC-Na solid medium, the ratio of the diameter of the hydrolysis zone to the colony diameter can reach 11. Enzyme activity identification results show that the filter paper enzyme activity of *Bacillus parabrachium* ABX1 is as high as 109.79 U·mL. ‑1 The exo-β-glucanase activity was 107.59 U·mL. ‑1 The cellulase activity reached 107.37 U·mL ‑1 It exhibits excellent cellulose and / or crystalline cellulose degradation capabilities; it is easy to use and has a wide range of enzyme production conditions, showing excellent enzyme activity at pH 5–10 and 25–50℃; the enzyme production time is short, with high enzyme yield achieved in just 12 hours, and there is no significant adverse effect on enzyme yield with prolonged reaction time; it is highly safe to use and has great application prospects in areas such as oak garden waste branch treatment, improvement of oak silkworm digestibility, industrial degradation of cellulose, and improvement of soil fertility.

The application discloses an automatic pressure regulating negative pressure suction device with automatic humidification function, which comprises a tracheal catheter, a closed sputum suction tube connected to the tail end of the tracheal catheter, a humidification tube connected to a humidification tube port on the closed sputum suction tube, an infusion device connected to the upper end of the humidification tube, sterile humidification liquid connected to the infusion device, a quantitative injection device additionally arranged outside a Murphy dropper of the infusion device, and a pressure pump provided with a volume sensor and a closed air bag wrapping the Murphy dropper, wherein the tail end of the closed sputum suction tube is connected to a disposable negative pressure suction liquid storage bottle through a suction device leather strap, and another connecting port of the negative pressure suction bottle is connected to a negative pressure suction pressure regulating table. According to the application, pressure modules are selected according to different suction liquids (sputum, bile, intestinal fluid, cerebrospinal fluid, etc.), a standard negative pressure value range is adjusted by one key, and the application is convenient to use. In addition, the automatic humidification can be performed on thick sputum for the sputum suction operation, the sputum is made to be thin, and the suction is facilitated.

This invention discloses a method for evaluating the bioavailability of soybean oil based on an in vitro digestion / cell co-culture model. Soybean oil is emulsified using WPI emulsifier and then digested sequentially through simulated gastric and intestinal fluids to obtain the gastric digestion products of soybean oil. Fatty acids are extracted from the intestinal digestion products of soybean oil, dissolved in dimethyl sulfoxide, and linked to fatty acid-free bovine serum albumin to obtain in vitro digestion products of soybean oil that can be absorbed by the intestines. These are then added to a cell co-culture model for cell incubation and transport. HepG2 cells from the cell co-culture model are collected, and Oil Red O staining and total triglyceride content are measured to obtain lipid deposition, thereby evaluating the bioavailability of soybean oil. The in vitro digestion / cell co-culture model of this invention is specifically designed for soybean oil digestion. This method objectively and scientifically evaluates the bioavailability of soybean oil at different metabolic stages, providing a standard basis for the scientific and healthy consumption of soybean oil and possessing significant practical value.

The invention provides pediococcus acidilactici with functions of improving emotion and intestinal health and application of the pediococcus acidilactici. The pediococcus acidilactici A25-4 is preserved in Guangdong Microbial Culture Collection Center on May 23, 2025, and the preservation number of the pediococcus acidilactici A25-4 is GDMCC NO: 66384. The pediococcus acidilactici A25-4 has better cholate resistance and artificial gastrointestinal fluid resistance and can produce indole lactic acid ILA at high yield, and the optimal carbon source is fructo-oligosaccharide and galactooligosaccharide. The pediococcus acidilactici A25-4 in-vivo intervention can significantly improve the symptoms of an irritable bowel syndrome model mouse, specifically, the anxiety mood of a tested object is significantly improved; the viscera hypersensitivity of a tested object is obviously relieved; excessive activation of mast cells of a tested object is obviously inhibited; the ILA level in a tested object is obviously improved.

The present application relates to the technical field of medical devices, and discloses an intestinal fluid intermittent return method and system based on pressure self-adaptation, wherein multi-modal sensor network is used to collect patient situation state, physiological rhythm and intestinal pressure data to obtain multi-dimensional monitoring data flow; time series signal processing technology is used to extract the corresponding phases of each data and calculate synchronization metrics; a synchronous state classification model is used for collaborative state classification; based on the classification result, a return decision instruction is generated to control the return device and adjust the return parameters according to the intestinal pressure; in addition, the present application also uses an incremental learning algorithm to adjust the model threshold and decision parameters based on individualized data sets, which can accurately control the return timing and parameters, and improve the return effect and safety of intestinal fluid.

Two-layer drug structure (1) comprising the following: an inner core (11) which is spherical in shape, wherein the inner core (11) contains a pharmaceutically active component; an enveloping polymer layer (12) having a thickness wherein the enveloping polymer layer (12) envelops the outer surface of the inner core (11), wherein the enveloping polymer layer (12) shrinks inwards in a gastric acid environment and swells outwards in an intestinal environment; and a multitude of hydrophilic pore-forming particles (13) embedded in the enclosing polymer layer (12), wherein the hydrophilic pore-forming particles (13) are exposed to the outside when the enclosing polymer layer (12) swells and dissolve in the intestinal fluid to form channels.

This invention discloses a traditional Chinese medicine composition for improving diarrhea, belonging to the field of traditional Chinese medicine technology. Addressing the shortcomings of existing antidiarrheal techniques, which only treat the symptoms and not the root cause, have significant side effects, high recurrence rates, and easily cause damage to the intestinal microcirculation, this invention is based on the original microscopic pathogenesis of small intestinal microvascular spasm and ischemia, and abnormal intestinal fluid metabolism. It is prepared by combining peppermint, angelica dahurica, nutmeg, cinnamon, platycodon grandiflorus, and angelica sinensis. The synergistic effect of each herb can target and relax spasmodic small intestinal microvessels, restore normal intestinal blood perfusion, regulate intestinal peristalsis rhythm, bidirectionally regulate intestinal fluid secretion and reabsorption, and simultaneously block abnormal stress signals in the brain-gut axis, repairing intestinal microcirculatory damage. This invention has a scientifically formulated composition, mild medicinal properties, and no side effects. It addresses the root causes of various acute, chronic, and functional diarrheas caused by cold stimulation, emotional stress, and spleen deficiency with cold stagnation, exhibiting strong curative effect and an extremely low recurrence rate, possessing high clinical promotion and application value.

The invention provides a roxburgh rose source intelligent delivery system and a preparation method and application thereof. The system is formed by self-assembling roxburgh rose endogenous components through physical field programming induction, and simultaneously meets the following requirements: (1) the molar ratio of Cu < 2 + > to Mn < 2 + > is (1: 5.5)-(1: 6.5), and the molar ratio of Cu < 2 + > to Sr < 2 + > is (1: 0.45)-(1: 0.51); (2) the Zeta potential is-5 mV to + 5 mV, and the conductivity is lt; 10 S / cm; (3) a release rate lt in simulated gastric juice; the release rate gt in simulated intestinal juice within 2 hours is 10%; 80%; and (4) in terms of solids, single administration MTD is greater than or equal to 5.0 g / kg. The system has nearly neutral Zeta potential and extremely low conductivity, keeps stable in long-term storage, can synergistically reduce serum uric acid, transaminase and blood sugar, and has a kidney protection effect while efficiently reducing uric acid. The invention further provides a green preparation method of the system and multi-field application of the system.

The application discloses a drug-loaded microalgae motor system for colon-targeted delivery and a preparation method and application thereof. The drug-loaded microalgae motor system comprises a Chlamydomonas reinhardtii microalgae motor core, the surface of the core is adsorbed with amino-modified ferroferric oxide nanoparticles through electrostatic adsorption, is wrapped with quercetin-modified chitosan quaternary ammonium salt, forms a nano-composite with magnetic responsiveness, and is encapsulated in a sodium alginate microsphere. The application utilizes Chlamydomonas reinhardtii as an antioxidant for adjuvant therapy, in a colon environment, the sodium alginate microsphere can be degraded in response to specific conditions, release the microalgae motor to autonomously move in intestinal fluid, and under the guidance of an external magnetic field, precisely target a lesion site in the intestinal tract. The application has good biocompatibility, biodegradability, gastric acid avoidance ability and magnetic / chemical dual driving targeting function, can effectively improve the treatment effect on colon diseases, and significantly reduce the systemic side effects of drugs, and expands the application of micro / nano motors in the biomedical field.

The oral composition according to the present invention contains an inorganic porous body, and when choline and primary / secondary / tertiary amine or ammonia, which are present as a mixture in an equal molar amount in an artificial intestinal juice, are mixed at a concentration of 2 g / L for 1 hour in an amount of 11.8 g per 1 mmol of choline, the adsorption rate of the primary / secondary / tertiary amine or ammonia is 60.0% or more, and the adsorption rate of choline is 40.0% or less. Alternatively, the oral composition according to the present invention contains a zeolite having an MFI structure and having a molar ratio of SiO2 to Al2O3 of 30.0 to 130000.0 (inclusive), or the zeolite having an FER structure and having a molar ratio of SiO2 to Al2O3 of 15.0 to 130000.0 (inclusive), or the oral composition according to the present invention contains a zeolite having an MFI structure and having a molar ratio of SiO2 to Al2O3 of 15.0 to 130000.0 (inclusive).

The invention relates to the field of probiotics, in particular to lactobacillus enteri LLM10, a probiotic complexing agent for promoting initial start of replacement gilts and oestrus of primiparous sows and application of the probiotic complexing agent. According to the present invention, the preservation number of the Lactobacillus enteri LLM10 is CGMCC No.26850, and the Lactobacillus enteri LLM10, the cinnamon powder and the Gorgon fruit powder are prepared into the complexing agent; the complexing agent can better enable the lactobacillus enteri LLM0 to be colonized in animal bodies, and has higher tolerance to artificial cholate, artificial gastric acid and artificial intestinal juice; particularly, hormone synthesis and secretion of the replacement gilts and the primiparous sows can be better improved, so that follicular development of the replacement gilts is improved, early starting of the replacement gilts is promoted, timely oestrus of the primiparous sows after weaning is promoted, the oestrus rate is increased, the pregnancy rate is increased, and the number of live piglets is increased.

The invention discloses an antihypertensive peptide capsule and a preparation method thereof, and relates to the technical field of peptide-containing pharmacy. The antihypertensive peptide capsule comprises an enteric capsule shell and a capsule content, the enteric capsule shell is not disintegrated within 2 hours in artificial gastric juice (pH 1.0-3.0) and disintegrated within 1 hour in artificial intestinal juice (pH 6.8-7.4); the capsule content consists of the following components in percentage by weight: 55 to 75 percent of microencapsulated traditional Chinese medicine compound filler, 15 to 30 percent of filler, 3 to 8 percent of flow aid and 5 to 12 percent of stabilizer. According to the antihypertensive peptide capsule and the preparation method thereof, decoction medicine is prepared into the capsule, the medicine is wrapped in the capsule in a particle form, a capsule shell can be dissolved within a few minutes after the capsule reaches the stomach, the medicine is gradually released in the process, and the situation that large-area and high-concentration liquid medicine instantly impacts gastric mucosa is avoided; and direct chemical stimulation and physical stimulation are obviously reduced.

The application provides a method for improving stability of lactobacillus plantarum, and relates to the field of lactobacillus plantarum preparation process. The process steps of the method for improving stability of lactobacillus plantarum are strain screening, candidate strain separation from traditional fermented food pickles, placing the pickle sample into a dilution tank, smearing the diluted pickle sample on MRS solid culture medium, placing the MRS solid culture medium into an anaerobic incubator, adjusting to 36 DEG C, anaerobic culture for 36 hours, picking single colonies for gram staining and peroxidase test to identify lactic acid bacteria, and placing the bacterial liquid in MRS liquid culture medium with pH 3.0 and standing for 3 hours to screen strains with a survival rate greater than 85%. The application utilizes the electrostatic adsorption principle of chitosan-sodium alginate to construct a pH-responsive microcapsule, the capsule shell is quickly swollen and releases the strain in an acidic environment, and the capsule shell remains intact in an alkaline environment, so that the colonization rate of the strain in simulated gastric and intestinal fluid is increased by 70%.

The invention relates to the technical field of medical equipment, in particular to a portable multifunctional intestinal juice feedback device which comprises a main body, the main body is provided with a first containing cavity, a second containing cavity, a third containing cavity and a driving assembly, and the driving assembly is connected with a drainage tube and the first containing cavity so that flushing fluid in the first containing cavity can be conveyed to the drainage tube for flushing; therefore, the condition of blockage can be avoided; or, a first cavity is formed in the side wall of the drainage tube, an ultrasonic assembly is arranged in the first cavity, and the other end of the ultrasonic assembly is used for acting ultrasonic mechanical vibration waves on the excrement so as to shatter the excrement, so that the blockage condition can be avoided; the driving assembly is connected with the first cavity and the first containing cavity so that the cooling liquid in the first containing cavity can be conveyed to the first cavity, and then the ultrasonic assembly can be cooled. The anti-blocking and filtering back-conveying device has multiple functions, and compared with two devices, the anti-blocking and filtering back-conveying device is more portable and more convenient to use.

The invention relates to the technical field of animal physiology research, and discloses a yak living gastric juice and intestinal juice sampling system and method capable of achieving segmented positioning, and the system comprises a negative pressure sampling unit, a plurality of positioning units, a physiological parameter sensing unit, a control unit and a multi-connected independent sample collection device. According to the method, real-time navigation is carried out through the sensor, the positioning unit is sequentially controlled to anchor different target parts of the digestive tract of the yak, and pure digestive juice samples are extracted respectively. The device solves the problems of inaccurate positioning, large trauma and easy sample pollution in the prior art, realizes noninvasive, accurate and repeatable collection of the gastrointestinal tract microorganism sample of the living yak, and is especially suitable for gastrointestinal tract microbiomics research.

The present invention provides a two-layer drug structure that allows the drug-active ingredient to be released slowly after entering the intestinal tract. [Solution] The drug has a two-layer structure comprising a spherical core 11 containing a drug active ingredient, a coating polymer layer 12 having a certain thickness that covers the outer surface of the core and contracts inward in the gastric acid environment and expands outward in the intestinal environment, and a plurality of hydrophilic pologen microparticles 13 embedded in the coating polymer layer that are exposed and dissolved in intestinal fluid when the coating polymer layer expands outward, and that form channels.

This invention discloses Akkermansia, its products and use, wherein the Akkermansia are Akkermansia guanciensis N21116 and N21169, with deposit numbers GDMCC No: 62888 and GDMCC No: 62889, respectively. Akkermansia guanciensis N21116 and N21169 in this invention are new species of Akkermansia that have the effect of tolerating artificial intestinal fluid and have antioxidant, tumor cell proliferation inhibitory, and weight loss / lipid reduction effects.

The present application belongs to the technical field of biological medicine, and particularly relates to a multifunctional peptide and application thereof in anti-inflammation, antibiosis, mucosa repair and intestinal secretion promotion. Specifically, the present application designs a polypeptide and analogs with both guanylate cyclase C receptor (GUCY2C) agonist activity and anti-inflammatory, antibacterial and mucosa repair functions. The polypeptide can not only bind with GUCY2C, stimulate the production of intracellular cyclic guanosine monophosphate (cGMP), promote intestinal fluid secretion, but also inhibit the release of pro-inflammatory factors, reduce inflammatory response, promote the repair of intestinal mucosa damaged, and inhibit the growth of opportunistic pathogenic bacteria, accelerate the recovery of intestinal homeostasis after intestinal preparation. While effectively promoting intestinal cleaning, the polypeptide does not cause intestinal inflammation and mucosa damage, has no hemolytic toxicity and cytotoxicity, is high in safety, and has a good clinical application prospect.

The invention relates to the technical field of microorganisms, in particular to lactobacillus acidophilus Deepsea100 with functions of reducing blood sugar, reducing fat and resisting aging and application of the lactobacillus acidophilus Deepsea100. The lactobacillus acidophilus Deepsea100 is separated from the intestinal tract of New Zealand longevity fish, and the preservation number is CGMCC No.36868. The scavenging rate of a fermented product to DPPH free radicals is larger than or equal to 96%, the scavenging rate to hydroxyl free radicals is larger than or equal to 83%, the inhibition rates to alpha-amylase, alpha-glucosidase and pancreatic lipase are larger than or equal to 71%, larger than or equal to 65% and larger than or equal to 66% respectively, and the lactobacillus acidophilus Deepsea100 has the effects of resisting oxidation, reducing blood sugar and fat and resisting aging, and can be used for preparing a feed additive. And the feed is strong in gastric acid intestinal juice resistance and intestinal colonization capacity, free of hemolytic reaction, sensitive to antibiotics and high in food safety. The invention also provides a microbial agent, a probiotic product, a fermentation product and the like containing the strain, can be applied to food, health care products, cosmetics or animal feeds, has the functions of prolonging the service life, enhancing the reproductive capacity and the like, and is remarkable in application value.

This invention provides a glycosylated peptide chelated iron pyrophosphate supplement, its preparation method, and its application. The raw materials for preparing the glycosylated peptide chelated iron pyrophosphate supplement include glycosylated peptides, iron pyrophosphate, and a solubilizer. The glycosylated peptide is a β-glucan-grafted casein phosphopeptide, and the solubilizer is sodium pyrophosphate. The glycosylated peptide chelated iron pyrophosphate supplement of this invention exhibits good water solubility, color stability over a wide pH range, coexistence with nutrients such as vitamin C and oils, high iron loading capacity, good stability in gastric juice, sustained iron release in simulated intestinal fluid, and high iron absorption and utilization rate, significantly improving anemia in iron-deficiency anemia mice. The excellent absorption performance and superior physicochemical properties of the glycosylated peptide chelated iron pyrophosphate supplement of this invention make it a potential candidate for widespread application in the iron supplement market.

The invention discloses a lactobacillus johnsonii YS my4 strain with a cryptosporidium infection resisting effect and application of the lactobacillus johnsonii YS my4 strain. The preservation number of the YS my4 strain is CCTCC (China Center For Type Culture Collection) M 20253011. The strain disclosed by the invention has the characteristics of cholate resistance, intestinal juice resistance, strong adhesiveness and capability of inhibiting salmonella and staphylococcus aureus. In addition, the strain has no hemolytic rings, and the strain has no influence on body indexes and can increase the body weight after gavage of suckling rats, so that the strain is proved to be high in safety and can be applied to the fields of medicine and food. According to the invention, the YS my4 strain is intragastrically fed to a pseudo-sterile suckling mouse infected by cryptosporidium parvum, and it is found that the strain can activate immune defense of the intestinal tract of a host by improving the MAPK phosphorylation level of the host in the state of cryptosporidium parvum infection, so that the insect loading amount of the cryptosporidium parvum is remarkably reduced; meanwhile, the YS my4 strain can improve the expression level of tight junction proteins Occludin and CLDN4, relieve pathological damage of ileum tissues and improve the intestinal barrier function, and has important application value in prevention and treatment of cryptosporidium parvum infection.

This invention relates to a strain of *Lactobacillus plantarum* with uric acid-lowering function (…). Lactobacillus plantarum YLW67 and its applications: This strain was isolated from red sour soup, a traditional fermented food from Guizhou, and is deposited at CGMCC, accession number No. 37373. This strain exhibits excellent tolerance to the gastrointestinal environment, with a survival rate exceeding 40% after treatment in simulated gastric fluid at pH 3.0 and simulated intestinal fluid at pH 8.0. In vitro experiments show that it can completely degrade inosine and guanosine within 9 hours. Animal experiments have confirmed that it can effectively reduce serum uric acid levels in hyperuricemia model mice. This invention also provides a probiotic composition containing this strain and its preparation method, including steps such as large-scale culture, cell collection, freeze-drying, and formulation. This strain and composition can be used to prepare uric acid-lowering functional foods, health foods, or dietary supplements, and have promising applications in improving hyperuricemia and related metabolic diseases.

The application discloses a palmitoyl hydrochloride-indometacin pharmaceutical cocrystal as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical crystallization. 21 H 22 ClNO4]·[C 19 H 16 ClNO4]. The palmitoyl hydrochloride-indometacin pharmaceutical cocrystal is prepared by mixing palmitoyl hydrochloride hydrate and indometacin in a solvent system according to a molar ratio of 1:1 and through stirring treatment in a suspended state. The process flow is simple, the operation is convenient, and the cocrystal has a high yield. In a pH 6.8 simulated intestinal fluid medium, the dissolution rate of palmitoyl hydrochloride in the pharmaceutical cocrystal is obviously lower than that of pure palmitoyl hydrochloride, and the pharmaceutical cocrystal presents a sustained-release behavior. On the contrary, the dissolution rate of indometacin in the pharmaceutical cocrystal is obviously improved, which is beneficial to the improvement of the bioavailability of indometacin. The palmitoyl hydrochloride-indometacin pharmaceutical cocrystal also has good human colon cancer cell inhibition activity.

The invention provides anti-PDCoV combined lactobacillus salivarius LSM237 and application thereof, and belongs to the technical field of microorganisms. The preservation number of the combined lactobacillus salivarius LSM237 is CCTCC (China Center For Type Culture Collection) NO: M 20252371. The probiotics are symbiotic probiotics in intestinal tracts, have the characteristics of high acid production capacity, acid resistance and bile salt resistance, have high endurance capacity to artificial gastrointestinal fluid, and can inhibit serratia marcescens, escherichia coli, staphylococcus aureus and salmonella typhimurium. The combined lactobacillus salivarius LSM237 has a remarkable anti-PDCoV effect, the anti-PDCoV infection capability of piglets can be improved, and clinical symptoms caused by PDCoV infection can be relieved. The combined lactobacillus salivarius LSM237 can regulate the immune system of a body and maintain the balance of intestinal flora of the body, can provide an application basis for developing a novel micro-ecological viable bacterium preparation for treating viral infection diseases of piglets, and can replace antibiotics to be applied to the micro-ecological viable bacterium preparation.